RT Journal Article SR Electronic T1 Effect of anakinra on mortality in COVID-19: a patient level meta-analysis JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.04.13.21255411 DO 10.1101/2021.04.13.21255411 A1 Evdoxia Kyriazopoulou A1 Thomas Huet A1 Giulio Cavalli A1 Andrea Gori A1 Miltiades Kyprianou A1 Peter Pickkers A1 Jesper Eugen-Olsen A1 Mario Clerici A1 Francisco Veas A1 Gilles Chatellier A1 Gilles Kaplanski A1 Mihai G. Netea A1 Emanuele Pontali A1 Marco Gattorno A1 Raphael Cauchois A1 Emma Kooistra A1 Matthijs Kox A1 Alessandra Bandera A1 Hélène Beaussier A1 Davide Mangioni A1 Lorenzo Dagna A1 Jos W. M. van der Meer A1 Evangelos J Giamarellos-Bourboulis A1 Gilles Hayem A1 International collaborative group for Anakinra in COVID-19 YR 2021 UL http://medrxiv.org/content/early/2021/04/19/2021.04.13.21255411.abstract AB Background Anakinra may represent an important therapy to improve the prognosis of COVID-19 patients. This meta-analysis using individual patient data was designed to assess the efficacy and safety of anakinra treatment in patients with COVID-19.Methods Based on a pre-specified protocol (PROSPERO: CRD42020221491), a systematic literature search was performed in MEDLINE (PubMed), Cochrane, medRxiv.org, bioRxiv.org and clinicaltrials.gov databases for trials in COVID-19 comparing administration of anakinra with standard-of-care and/or placebo. Individual patient data from eligible trials were requested. The primary endpoint was the mortality rate and the secondary endpoint was safety.Findings Literature search yielded 209 articles, of which 178 articles fulfilled screening criteria and were full-text assessed. Aggregate data on 1185 patients from 9 studies were analyzed and individual patient data on 895 patients from 6 studies were collected. Most studies used historical controls. Mortality was significantly lower in anakinra-treated patients (38/342 [11·1%]) as compared with 137/553 (24·8%) observed in patients receiving standard-of-care and/or placebo on top of standard-of-care (137/553 [24·8%]); adjusted odds ratio (OR), 0·32; 95% CI, 0·20 to 0·51; p <0·001. The mortality benefit was similar across subgroups regardless of diabetes mellitus, ferritin concentrations, or baseline P/F ratio. The effect was more profound in patients exhibiting CRP levels >100 mg/L (OR 0·28,95%CI 0·27-1·47). Safety issues, such as increase of secondary infections, did not emerge.Interpretation Anakinra may be a safe anti-inflammatory treatment option in patients hospitalized with moderate-to-severe COVID-19 pneumonia to reduce mortality, especially in the presence of hyperinflammation signs such as CRP>100mg /L.Funding Sobi.Evidence before this study Since the emergence of the COVID-19 pandemic, numerous drugs have been tried in an effort to prevent major detrimental consequences, such as respiratory and multiorgan failure and death. Early during the pandemic, it was realized that drugs aiming to regulate the immune host reaction may play an important role in the treatment of COVID-19. Evidence from a small number of patients with moderate or severe COVID-19 treated with anakinra, and interleukin-1 receptor antagonist, has suggested therapeutic efficacy. We systematically searched all available literature and aimed to present cumulative evidence of anakinra treatment in COVID-19 and the related effect on mortality.Added value of this study This is the first patient-level analysis on the effect of anakinra treatment in COVID-19 patients, which, on the one hand, suggests a significant benefit in the reduction of mortality and on the other hand, reassures safety of the treatment. Most importantly, the current study identifies a subgroup of patients with CRP>100mg/L, that may benefit most from treatment with anakinra. Confirmation of these effects in larger randomized clinical trials (RCTs) is urgently needed.Implications of all the available evidence Anakinra may be an effective and safe immunomodulatory treatment in moderate-to-severe cases of pneumonia due to COVID-19 to prevent unfavorable outcomes. Anakinra may be helpful to avoid adverse events, such as breakthrough infections observed often with dexamethasone use, and may be considered an alternative in specific subgroups of patients e.g. diabetics. Larger trials, summarized in the Table, are ongoing and their results are urgently needed to investigate anakinra’s best place in the treatment of COVID-19.View this table:Competing Interest StatementE.J.Giamarellos-Bourboulis has received honoraria from AbbVie USA, Abbott CH, Biotest Germany, Brahms GmbH, InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent educational grants from AbbVie, Abbott CH, Astellas Pharma Europe, AxisShield, bioMerieux Inc, InflaRx GmbH, the Medicines Company and XBiotech Inc.; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). M.G.Netea is supported by an ERC Advanced Grant (#833247) and a Spinoza grant of the Netherlands Organization for Scientific Research. He has also received independent educational grants from TTxD, GSK and ViiV HealthCare.M. Gattorno has received speakers' fees and unrestricted grants from Novartis and Sobi.Jesper Eugen-Olsen is a co-founder, shareholder and CSO of ViroGates, Denmark, and named inventor on patients on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark.G. Kaplanski has received fees from Sobi France for scientific presentations.G. Cavalli and L. Dagna have received consultation honoraria from Sobi. The other authors do not have any competing interest to declare.Clinical TrialNot applicableClinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=221491 Funding StatementSobi supported this study. The funder had no role in design, study conduct, analysis, interpretation of data or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data are included in manuscript and supplement.